Physician profile
Thomas Klis
NPI 1952833154
$7,824.35
in general payments reported to CMS, 2019-2025
26 companies · $2,427 in 2025
The $2,427 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $289 · 2021: $656 · 2022: $438 · 2023: $1,137 · 2024: $2,150 · 2025: $2,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,451 · Education: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,451.41 |
| Education | $262.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,458.97 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,148.21 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $1,087.76 | 2024-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $810.59 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Lilly USA, LLC | $576.58 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Galderma Laboratories, L.P. | $426.29 | 2023-2025 | Nemluvio, Aklief, Oracea |
| Novartis Pharmaceuticals Corporation | $379.89 | 2024-2025 | |
| Genzyme Corporation | $345.66 | 2019-2025 | |
| Dermavant Sciences, INC. | $318.56 | 2023-2024 | Vtama |
| Incyte Corporation | $266.22 | 2021-2025 | Opzelura |
| Pfizer INC. | $214.31 | 2021-2025 | |
| Almirall LLC | $108.56 | 2021-2025 | Klisyri, Seysara |
| Sanofi-Aventis U.S. LLC | $98.61 | 2019 | |
| Allergan, INC. | $97.33 | 2019 | |
| Organon LLC | $91.28 | 2025 | Vtama, Nexplanon |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $75.91 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.34 | 2025 | Spevigo |
| Verrica Pharmaceuticals INC. | $56.33 | 2024-2025 | Ycanth |
| Arcutis Biotherapeutics, INC. | $49.51 | 2024-2025 | Zoryve |
| Epi Health, LLC | $35.88 | 2022 | |
| Amgen INC. | $31.36 | 2022 | |
| Leo Pharma INC. | $22.64 | 2024 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $18.57 | 2023 | Sotyktu |
| Celgene Corporation | $15.96 | 2019 | |
| Merz North America, INC. | $15.31 | 2019 | |
| Journey Medical Corporation | $13.72 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Klis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.